Human anti-alpha-synuclein antibodies
AssigneesBiogen Idec International Neuroscience GmbH, University of Zurich
InventorsAndreas Weihofen, Jan Grimm, Roger Nitsch, Christoph Hock
Life of this patent
Estimating the term…
Abstract
Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for α-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for α-synuclein targeted immunotherapy and diagnosis, respectively.
Claims26
A human monoclonal anti-α-synuclein antibody, or an α-synuclein binding fragment thereof comprising:
- a VH CDR1 comprising residues 31-35 of SEQ ID NO:9, a VH CDR2 comprising residues 50-68 of SEQ ID NO:9, a VH CDR3 comprising residues 101-102 of SEQ ID NO:9, a VL CDR1 comprising residues 23-33 of SEQ ID NO:12, a VL CDR2 comprising residues 49-55 of SEQ ID NO:12, and a VL CDR3 comprising residues 88-98 of SEQ ID NO:12.
A human monoclonal anti-α-synuclein antibody, or an α-synuclein binding fragment thereof comprising:
- a VH CDR1 comprising residues 31-35 of SEQ ID NO:3, a VH CDR2 comprising residues 50-66 of SEQ ID NO:3, a VH CDR3 comprising residues 99-110 of SEQ ID NO:3, a VL CDR1 comprising residues 23-33 of SEQ ID NO:6, a VL CDR2 comprising residues 49-55 of SEQ ID NO:6, and a VL CDR3 comprising residues 88-98 of SEQ ID NO:6.
A human monoclonal anti-α-synuclein antibody, or an α-synuclein binding fragment thereof comprising:
- a VH CDR1 comprising residues 31-35 of SEQ ID NO:15, a VH CDR2 comprising residues 50-66 of SEQ ID NO:15, a VH CDR3 comprising residues 99-112 of SEQ ID NO:15, a VL CDR1 comprising residues 24-34 of SEQ ID NO:18, a VL CDR2 comprising residues 50-56 of SEQ ID NO:18, and a VL CDR3 comprising residues 89-96 of SEQ ID NO:18.
A human monoclonal anti-α-synuclein antibody, or an α-synuclein binding fragment thereof comprising:
- a VH CDR1 comprising residues 31-35 of SEQ ID NO:15, a VH CDR2 comprising residues 50-66 of SEQ ID NO:15, a VH CDR3 comprising residues 99-112 of SEQ ID NO:15, a VL CDR1 comprising residues 24-34 of SEQ ID NO:21, a VL CDR2 comprising residues 50-56 of SEQ ID NO:21, and a VL CDR3 comprising residues 89-97 of SEQ ID NO:21.
A human monoclonal anti-α-synuclein antibody, or an α-synuclein binding fragment thereof comprising:
- a) a VH region comprising the amino acid sequence of SEQ ID NO:10 and
- b) a VL region comprising the amino acid sequence of SEQ ID NO:13.
A human monoclonal anti-α-synuclein antibody, or an α-synuclein binding fragment thereof comprising:
- a) a VH region comprising the amino acid sequence of SEQ ID NO:4 and
- b) a VL region comprising the amino acid sequence of SEQ ID NO:7.
A human monoclonal anti-α-synuclein antibody, or an α-synuclein binding fragment thereof comprising:
- a) a VH region comprising the amino acid sequence of SEQ ID NO:16 and
- b) a VL region comprising the amino acid sequence of SEQ ID NO:19.
A human monoclonal anti-α-synuclein antibody, or an α-synuclein binding fragment thereof comprising:
- a) a VH region comprising the amino acid sequence of SEQ ID NO:16 and
- b) a VL region comprising the amino acid sequence of SEQ ID NO:22.
Dependencies are inferred from the claim text.